|
n = 110 patients
|
Median / n (% / range)
|
|---|
|
Age
|
59.4 (25–82)
|
|
Sex
|
|
Male
|
64 (58.2)
|
|
Female
|
44 (44.0)
|
|
ECOG
|
|
0
|
77 (70.0)
|
|
1
|
26 (23.6)
|
|
2
|
6 (5.5)
|
|
3
|
1 (0.9)
|
|
Number of brain metastases
|
median: 2 (1–30)
|
|
1
|
47 (42.7)
|
|
2–4
|
53 (48.1)
|
|
> 4
|
10 (9.0)
|
|
BRAF status
|
|
positive
|
57 (48.2)
|
|
negative/unknown
|
46 (41.8) / 7 (6.3)
|
|
extracranial metastases
|
|
yes
|
83 (75.5)
|
|
no
|
27 (24.5)
|
|
volume of brain metastases
|
|
≥ 1.5 cc
|
55 (50.0) 1.5–24.54 cc
|
|
< 1.5 cc
|
55 (50.0) 0.05–1.4 cc
|
|
RT regimen
|
|
SRS
|
95 (86.4)
|
|
SRT
|
15 (13.6)
|
|
Concomitant systemic therapy
|
|
IT
|
67 (60.9)
|
|
TT
|
34 (30.9)
|
|
combination
|
9 (8.2)
|
- Abbreviations: SRS Stereotactic radiosurgery, SRT Stereotactic radiotherapy, IT Immunotherapy, TT Targeted therapy
